Member Info for Paperstraw

Without an RNS the market wont gap more than 10% imo, it’ll be arbitrary though as agreed before anyone can get anywhere near a buy it’ll have bagged+

Yes sorry, gap up .5p then fly on 7.30% being bought all at once

Could gap .5p in the morn imo, but the main impact will be everyone running to close their shorts...you imagine the impact buying 7.3% at best market rate at the same time is going to have.... pleased i didn't just flip for 20% today and hung on. Good luck everyone

You could see the buy order sitting there, kept bouncing off it.

You've been posting regularly since before 6am today. Maybe close your short and get out for your own well being, not worth the stress!

Anyone else agree?

Apologies if already posted, but I thought a good read and reference to us:

https://www.itnonline.com/content/delta-t1-maps-provide-quantitative-automated-solution-assess-brain-tumor-burden

https://lse.swingtradebot.com/equities/IQAI:LSE

Race in the morning to see who can get to the cheap ones first hopefully!!

Strange to mention it under Flying Brands [now IQAI], makes me think it’s not a commissioned article and probably why it’s been missed, good read: “[...]leading players in the market are looking forward to leverage new opportunities created from incorporation of artificial intelligence (AI), as home screening of kidney stones is likely to create lucrative opportunities for manufacturers. Flying Brands’ acquisition of Imaging Biometrics (IB) was aimed to leverage its expertise in machine learning and artificial intelligence to imaging[...)” https://newstechmarkets.com/2019/06/21/kidney-stone-management-devices-market-sales-from-prime-geographies-projected-to-motivate-growth-during-2018-to-2028/ And “[...] kidney stone management devices market including Siemens Healthineers AG, Dornier MedTech (Subsidiary of Accuron MedTech), Lumenis Ltd., STORZ MEDICAL AG, Inceler Medikal Co. Ltd., DirexGroup, Medispec Ltd., EDAP TMS S.A., GEMSS Co., Ltd. and Richard Wolf GmbH. [...]” https://www.factmr.com/report/1827/kidney-stone-management-devices-market And that’s just Stonechecker....no reason we shouldn’t be bullish if these guys are!

Always said he thought it should be sitting at around 6p pre-FDA ( see interviews from Q3/Q4 last year) and thats without pricing in Cortechs, the sales and the software development of the last 9 months